期刊
MULTIPLE SCLEROSIS JOURNAL
卷 25, 期 3, 页码 399-407出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458518754364
关键词
Pediatric; multiple sclerosis; long; follow-up; childhood; child
Background: Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs). Objectives: To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents. Methods: Data regarding treatments, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and serious adverse event were collected. Baseline characteristics were tested in multivariate analysis to identify predictors of disease evolution. Results: In total, 97 patients were followed for 12.53.3years. They started therapy at 13.9 +/- 2.1years, 88 with interferons and 9 with copaxone. During the whole follow-up, 82 patients changed therapy, switching to immunosuppressors/second-line treatment in 58% of cases. Compared to pre-treatment phase, the ARR was significantly reduced during the first treatment (from 3.2 +/- 2.6 to 0.7 +/- 1.5, p<0.001), and it remained low during the whole follow-up (0.3 +/- 0.2, p<0.001). At last observation, 40% had disability worsening, but EDSS score remained <4 in 89%. One patient died at age of 23years due to MS. One case of natalizumab-related progressive multifocal encephalopathy (PML) was recorded. Starting therapy before 12years of age resulted in a better course of disease in multivariate analysis. Conclusion: Pediatric-MS patients benefited from interferons/copaxone, but the majority had to switch to more powerful drugs. Starting therapy before 12years of age could lead to a more favorable outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据